Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Koji Sasaki, MD, Christopher B. Benton, MD, Kelly Soltysiak, PhD, Elias Jabbour, MD, Tapan M. Kadia, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Mark Routbort, MD PhD, Irene Ganan-Gomez, PhD, Yue Wei, PhD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kim-Anh Do, PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 1719.

https://doi.org/10.1182/blood-2019-130545

Published: 2019

Journal Articles

Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome

Koji Sasaki, MD, Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Graciela M. Nogueras González, MPH, Keyur Patel, MD PhD, Kelly Soltysiak, PhD, Junya Sato, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 1720.

https://doi.org/10.1182/blood-2019-130155

Published: 2019

Journal Articles

Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes

Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Irene Ganan-Gomez, PhD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Guillaume Richard-Carpentier, MD, Kiran Naqvi, MDMPH, Yue Wei, PhD, Hui Yang, PhDMD, Kelly Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Kim-Anh Do, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 3006.

https://doi.org/10.1182/blood-2019-124957

Published: 2019

Journal Articles

KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice

Yue Wei, PhD, Hong Zheng, Naran Bao, Rashmi Kanagal-Shamanna, MD, Caleb Class, PhD, Hui Yang, PhDMD, Guillermo Montalban Bravo, MD, Irene Ganan-Gomez, PhD, Kelly Soltysiak, PhD, Kim-Ann Do, Simona Colla, PhD, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 562.

https://doi.org/10.1182/blood-2019-122574

Published: 2019

Journal Articles

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Michael Andreeff, MD PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4240.

https://doi.org/10.1182/blood-2019-129598

Published: 2019

Journal Articles

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

Kelly S. Chien, MD, Mahesh Swaminathan, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Nicholas J. Short, MD, Kelly Soltysiak, PhD, Sherry A. Pierce, BSN, BA, Jane Waukau, BSN, RN, Darla Miller, Jorge E. Cortes, MD, Yesid Alvarado, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4252.

https://doi.org/10.1182/blood-2019-129226

Published: 2019

Journal Articles

The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

Kelly S. Chien, MD, Rashmi Kanagal-Shamanna, MD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Yesid Alvarado, MD, Koichi Takahashi, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Mark Routbort, MD PhD, Sherry A. Pierce, BSN, BA, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD

Blood (2019) 134 (Supplement_1): 1436.

https://doi.org/10.1182/blood-2019-131188

Published: 2019

Journal Articles

The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Blood (2019) 134 (Supplement_1): 1642.

https://doi.org/10.1182/blood-2019-130148

Published: 2019

Journal Articles

Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab

Hui Yang, PhDMD, Zhihong Fang, Karen Clise-Dwyer, PhD, Kathryn Ruisaard, Simona Colla, PhD, Irene Ganan-Gomez, PhD, Guillermo Montalban-Bravo, MD, Kelly Soltysiak, Naval G. Daver, MD, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2018) 132 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2018-99-119278

Published: 2018

NARROW

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome

Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes

KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only